Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heart SHOCK-NORDOB: norepinephrine vs norepinephrine + dobutamine in cardiogenic shock
2017-001270-41Phase 3Active
- Sponsor
- CHRU Nancy
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cardiogenic shock comparing Norepinephrine alone first with Norepinephrine + dobutamine first (2 arms). Primary endpoint: Composite efficacy endpoint. Started Jun 2017; status: active.
02
Drugs
norepinephrinedobutamine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2017-001270-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001270-41.